Takeda ALK inhibitor Alunbrig (brigatinib) stage 3 clinical trial shows good long-term efficacy
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Takeda(http:// announcedthat its next-generation ALK inhibitor, Alunbrig (brigatinib), had shown good long-term efficacy in the treatment of alK-positive non-small cell lung cancer (NSCLC) patients in phase 3 clinicaltrial(http://About Alunbrig
Alunbrig was able to reduce the risk of disease progression or death by 57% compared to common generation ALK inhibitorsIn patients with brain metastasis, Alunbrig was able to reduce the risk of progression or death by 76%Alunbrig is the next generation of tyrosine kinase inhibitors (TKI) developed by Takeda, which are designed to target and inhibit ALK fusion proteinsIn April 2017, it received accelerated approval from theFDA(http://to treat PATIENTs with ALK-positive metastatic NSCLCThese patients continued to progress after receiving crizotinib treatmentAbout ALTA-1L 275 PATIENTS WITH ADVANCED OR METASTATIC NSCLC WHO WERE TREATED WITH ALUNBRIG OR CRIZOTINIB IN AN OPEN LABEL CALLED ALTA-1L, A RANDOMIZED MULTICENTER PHASE 3 CLINICAL TRIAL The patient was not previously treated with ALK inhibitors The results showed that the non-progressive life span (PFS) in patients in the Alunbrig group was 29.4 months, compared with 9.2 months in the active control group For patients with brain metastasis, PFS in the Alunbrig group was 24 months and the active control group was 5.6 months Alunbrig also significantly improves the quality of life of patients
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
